Last month's release of "I am not the God of medicine" has aroused a lot of people's sympathy. Tens of thousands of anti-cancer drugs are too easy for ordinary families to bear. Recently, the National Health Insurance Bureau has made it clear that 14 kinds of anti-cancer drugs are on sale.
The reporter learned from the state medical insurance bureau that in order to further reduce the economic burden of cancer patients, the State Medical Insurance Bureau has lowered the payment standard and purchase price of 14 kinds of anticancer drugs negotiated by the state in the early stage, and required that all provincial drug centralized purchase platforms should open online purchase according to the adjusted new price before the end of September.
It is understood that the State Medical Insurance Bureau recently issued the notice on the early national negotiation on the payment standard and purchase price adjustment of anti-cancer drug medical insurance. According to the requirements of the notice, enterprises related to anticancer drugs will actively submit the price adjustment application to the provincial drug bidding and purchasing departments within the specified time, and the local drug bidding and purchasing departments shall strengthen communication with enterprises, and timely hang the network according to the new price. It is expected that from September, patients will be able to buy anti-cancer drugs after price reduction.
The head of the National Health Insurance Bureau said that in the next step, the National Health Insurance Bureau will strengthen guidance, do a good job in the implementation of the new price of anti-cancer drugs, so that the masses of the people can get real benefits as soon as possible. At the same time, the national health insurance bureau is carrying out special negotiations on medical insurance access for exclusive anti-cancer drugs out of some catalogues, so as to further reduce the burden on patients.
It is understood that the National Health Insurance Bureau has organized experts to determine the scope of drugs to be negotiated for medical insurance access through review, selection and voting procedures. Currently, it is confirming the willingness of negotiation with enterprises. Next, it will start the preparation of negotiation materials, expert evaluation and specific negotiation. According to the head of the National Health Insurance Bureau, all the drugs proposed by the experts are of high clinical value, high innovation and high benefit for patients, which are necessary for the treatment of blood tumors and solid tumors. They cover multiple cancer types such as non-small cell lung cancer, colorectal cancer, renal cell cancer, melanoma, chronic myeloid leukemia, lymphoid cancer and multiple myeloma.